{"entity":{"id":"gc012f","kind":"drug","name":"GC012F","aka":[],"tldr":"GC012F is an experimental CAR-T cell therapy from Gracell Biotechnologies (Shanghai) in phase 2 trials for multiple myeloma, aimed at CD19 and BCMA.","summary":"GC012F is a CAR-T cell therapy developed by Gracell Biotechnologies (Shanghai). Its targets are CD19 and BCMA (the sponsor names BCMA x CD19). The sponsor states: A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT06235229, plans to enrol 110 participants with primary completion was scheduled for 2026-03-02 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of GC012F","url":"https://clinicaltrials.gov/search?intr=GC012F"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":["cd19","bcma"],"drugs":[],"companies":["gracell-biotechnologies","astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06235229"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"A dual chimeric antigen receptor (CAR) T-cell product engineered to recognise and attack multiple myeloma cells expressing either BCMA or CD19.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gc012f/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","route":"/companies/gracell-biotechnologies/"}],"trial":[{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06235229/"}]}}